Your browser is no longer supported. Please, upgrade your browser.
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.25 Insider Own0.90% Shs Outstand71.75M Perf Week-0.69%
Market Cap2.71B Forward P/E- EPS next Y-3.40 Insider Trans-19.14% Shs Float- Perf Month7.56%
Income-155.80M PEG- EPS next Q-0.77 Inst Own93.80% Short Float- Perf Quarter48.40%
Sales57.80M P/S46.93 EPS this Y6.70% Inst Trans0.43% Short Ratio6.01 Perf Half Y38.75%
Book/sh0.23 P/B142.91 EPS next Y-4.70% ROA-29.00% Target Price45.30 Perf Year54.54%
Cash/sh4.24 P/C7.74 EPS next 5Y15.00% ROE-179.40% 52W Range14.71 - 34.45 Perf YTD58.18%
Dividend- P/FCF- EPS past 5Y-15.30% ROI-37.70% 52W High-4.59% Beta1.38
Dividend %- Quick Ratio5.90 Sales past 5Y14.30% Gross Margin- 52W Low123.45% ATR1.56
Employees184 Current Ratio5.90 Sales Q/Q-22.20% Oper. Margin- RSI (14)56.03 Volatility4.50% 5.07%
OptionableYes Debt/Eq8.44 EPS Q/Q-25.40% Profit Margin- Rel Volume0.26 Prev Close32.87
ShortableYes LT Debt/Eq7.75 EarningsAug 05 AMC Payout- Avg Volume1.88M Price32.87
Recom2.10 SMA201.82% SMA509.15% SMA20036.71% Volume0 Change0.00%
Mar-12-21Initiated Wolfe Research Outperform $50
Feb-18-21Initiated Barclays Overweight $28
Jan-20-21Reiterated H.C. Wainwright Buy $22 → $41
Oct-29-20Initiated Goldman Neutral $16
Jul-10-20Initiated Raymond James Strong Buy $39
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Sep-12-21 11:45AM  
Sep-08-21 04:00PM  
Sep-07-21 07:30AM  
Sep-01-21 04:00PM  
Aug-31-21 09:07AM  
07:30AM  
Aug-27-21 10:13AM  
Aug-19-21 07:30AM  
Aug-18-21 09:06AM  
Aug-06-21 08:01AM  
Aug-05-21 05:15PM  
04:00PM  
Aug-02-21 04:00PM  
07:30AM  
Jul-29-21 03:04PM  
Jul-23-21 12:45PM  
Jul-22-21 04:00PM  
Jul-21-21 06:05PM  
Jul-20-21 08:43AM  
Jul-19-21 05:11PM  
04:20PM  
04:00PM  
02:32PM  
02:06PM  
12:28PM  
08:13AM  
08:12AM  
07:40AM  
07:36AM  
06:00AM  
Jul-06-21 11:47AM  
Jul-01-21 04:00PM  
Jun-30-21 07:30AM  
Jun-23-21 07:30AM  
Jun-15-21 07:30AM  
Jun-02-21 04:00PM  
Jun-01-21 04:00PM  
May-19-21 07:30AM  
May-17-21 01:02PM  
08:00AM  
May-16-21 08:00AM  
May-11-21 01:41AM  
May-10-21 04:00PM  
May-07-21 04:01AM  
May-06-21 06:15PM  
04:00PM  
02:30PM  
07:30AM  
May-05-21 04:00PM  
08:24AM  
May-04-21 07:30AM  
May-03-21 04:00PM  
02:48PM  
07:00AM  
Apr-22-21 04:00PM  
Apr-20-21 11:56AM  
Apr-12-21 07:30AM  
Apr-05-21 04:00PM  
Apr-02-21 04:00PM  
Apr-01-21 04:00PM  
Mar-18-21 07:30AM  
07:23AM  
Mar-02-21 04:00PM  
Feb-26-21 04:32PM  
07:30AM  
02:30AM  
Feb-25-21 04:00PM  
02:30PM  
Feb-18-21 07:30AM  
02:39AM  
Feb-14-21 01:32PM  
Feb-11-21 04:00PM  
Feb-02-21 07:30AM  
Feb-01-21 04:00PM  
Jan-13-21 07:30AM  
Jan-11-21 07:30AM  
Jan-06-21 04:00PM  
Dec-23-20 07:30AM  
Dec-19-20 02:44PM  
Dec-14-20 07:30AM  
Dec-09-20 07:30AM  
Dec-07-20 07:30AM  
Dec-03-20 07:30AM  
Dec-01-20 04:00PM  
07:30AM  
Nov-29-20 06:44AM  
Nov-24-20 04:00PM  
03:07PM  
Nov-23-20 07:30AM  
Nov-20-20 07:30AM  
Nov-16-20 07:30AM  
07:30AM  
Nov-13-20 11:53AM  
11:35AM  
11:35AM  
Nov-10-20 04:00PM  
Nov-06-20 07:30AM  
06:13AM  
Nov-04-20 10:32PM  
05:15PM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blum Robert IPresident & CEOSep 15Option Exercise6.245,00031,220361,628Sep 17 04:25 PM
Blum Robert IPresident & CEOSep 15Sale32.665,000163,316357,563Sep 17 04:25 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 09Sale31.432,00062,860152,878Sep 09 07:17 PM
Blum Robert IPresident & CEOSep 02Option Exercise6.305,00031,500362,563Sep 03 04:24 PM
Blum Robert IPresident & CEOSep 02Sale33.125,000165,577357,563Sep 03 04:24 PM
Cragg DavidChief HR & Admin OfficerSep 01Sale32.787,850257,311144,692Sep 02 04:08 PM
Blum Robert IPresident & CEOAug 18Option Exercise6.305,00031,500362,563Aug 20 04:28 PM
Blum Robert IPresident & CEOAug 18Sale31.145,000155,712357,563Aug 20 04:28 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 12Sale32.602,00065,200154,878Aug 13 05:09 PM
Blum Robert IPresident & CEOAug 05Option Exercise6.305,00031,500362,563Aug 06 04:19 PM
Blum Robert IPresident & CEOAug 05Sale29.125,000145,604357,563Aug 06 04:19 PM
Cragg DavidChief HR & Admin OfficerAug 02Sale29.672,61677,617152,542Aug 02 06:59 PM
Blum Robert IPresident & CEOJul 22Option Exercise6.305,00031,500362,563Jul 23 05:02 PM
Blum Robert IPresident & CEOJul 22Sale29.825,000149,121357,563Jul 23 05:02 PM
SMITH SANDFORD DDirectorJul 19Option Exercise10.6811,965127,78611,459Jul 21 05:14 PM
SMITH SANDFORD DDirectorJul 19Sale28.8711,965345,4686,459Jul 21 05:14 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 08Sale19.482,00038,952156,878Jul 08 05:32 PM
Blum Robert IPresident & CEOJul 06Option Exercise6.305,00031,500362,563Jul 06 05:42 PM
Blum Robert IPresident & CEOJul 06Sale20.135,000100,668357,563Jul 06 05:42 PM
Blum Robert IPresident & CEOJun 18Option Exercise6.305,00031,500362,563Jun 21 05:24 PM
Blum Robert IPresident & CEOJun 18Sale21.375,000106,838357,563Jun 21 05:24 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 10Sale21.482,00042,952158,878Jun 10 04:28 PM
Blum Robert IPresident & CEOJun 03Option Exercise6.305,00031,500362,563Jun 04 06:28 PM
Blum Robert IPresident & CEOJun 03Sale20.615,000103,044357,563Jun 04 06:28 PM
Cragg DavidChief HR & Admin OfficerJun 01Option Exercise6.3014,99994,494169,608Jun 02 04:45 PM
Cragg DavidChief HR & Admin OfficerJun 01Sale21.6314,999324,389161,171Jun 02 04:45 PM
Blum Robert IPresident & CEOMay 20Option Exercise6.305,00031,500361,859May 24 04:32 PM
Blum Robert IPresident & CEOMay 20Sale23.715,000118,549356,859May 24 04:32 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 13Sale24.422,00048,840160,348May 13 08:02 PM
Blum Robert IPresident & CEOMay 07Option Exercise6.305,00031,500361,859May 07 06:46 PM
Blum Robert IPresident & CEOMay 07Sale23.215,000116,041356,859May 07 06:46 PM
Blum Robert IPresident & CEOApr 30Option Exercise6.305,00031,500361,859Apr 30 05:46 PM
Blum Robert IPresident & CEOApr 30Sale25.875,000129,361356,859Apr 30 05:46 PM
SMITH SANDFORD DDirectorApr 27Option Exercise10.629,739103,3965,920Apr 27 05:40 PM
SMITH SANDFORD DDirectorApr 27Sale27.769,739270,322920Apr 27 05:40 PM
SMITH SANDFORD DDirectorApr 26Option Exercise9.455,00047,2505,920Apr 27 04:47 PM
SMITH SANDFORD DDirectorApr 26Sale27.005,000135,000920Apr 27 04:47 PM
SMITH SANDFORD DDirectorApr 23Option Exercise9.455,00047,2505,920Apr 23 05:32 PM
SMITH SANDFORD DDirectorApr 23Sale26.505,000132,500920Apr 23 05:32 PM
SMITH SANDFORD DDirectorApr 15Option Exercise9.0810,71497,2486,634Apr 15 06:55 PM
SMITH SANDFORD DDirectorApr 15Sale25.2310,714270,350920Apr 15 06:55 PM
Blum Robert IPresident & CEOApr 12Option Exercise6.305,00031,500361,859Apr 12 05:31 PM
Blum Robert IPresident & CEOApr 12Sale23.565,000117,813356,859Apr 12 05:31 PM
SMITH SANDFORD DDirectorApr 09Option Exercise7.9027,582217,8225,920Apr 12 04:21 PM
SMITH SANDFORD DDirectorApr 09Sale23.9327,582659,990920Apr 12 04:21 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 08Sale23.392,00046,772162,348Apr 08 06:12 PM
HENDERSON JOHN TDirectorApr 01Option Exercise8.643,33328,7978,543Apr 05 06:50 PM
HENDERSON JOHN TDirectorApr 01Sale23.543,33378,4747,410Apr 05 06:50 PM
Blum Robert IPresident & CEOMar 22Option Exercise6.035,00030,170361,293Mar 24 04:13 PM
Blum Robert IPresident & CEOMar 22Sale25.195,000125,972356,859Mar 24 04:13 PM
GAGE L PATRICKDirectorMar 19Option Exercise5.8810,00058,80031,762Mar 19 06:55 PM
GAGE L PATRICKDirectorMar 19Sale24.4510,000244,46821,762Mar 19 06:55 PM
GAGE L PATRICKDirectorMar 12Option Exercise6.7710,33969,99228,768Mar 12 06:58 PM
GAGE L PATRICKDirectorMar 12Sale21.2210,339219,37221,762Mar 12 06:58 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 11Sale19.902,00039,798164,348Mar 11 04:50 PM
Blum Robert IPresident & CEOMar 08Option Exercise6.005,00030,000385,658Mar 08 06:10 PM
Blum Robert IPresident & CEOMar 08Sale19.495,00097,472380,658Mar 08 06:10 PM
Blum Robert IPresident & CEOFeb 26Option Exercise6.005,00030,000339,373Feb 26 06:25 PM
Blum Robert IPresident & CEOFeb 26Sale19.335,00096,651334,373Feb 26 06:25 PM
Blum Robert IPresident & CEOFeb 18Option Exercise9.4283,332784,987382,269Feb 22 05:17 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 11Sale23.341,63238,097148,809Feb 12 05:37 PM
Blum Robert IPresident & CEOFeb 10Option Exercise6.005,00030,000310,589Feb 12 05:36 PM
Blum Robert IPresident & CEOFeb 10Sale23.885,000119,384305,589Feb 12 05:36 PM
Blum Robert IPresident & CEOJan 29Option Exercise6.005,00030,000310,589Jan 29 05:17 PM
Blum Robert IPresident & CEOJan 29Sale20.345,000101,701305,589Jan 29 05:17 PM
Blum Robert IPresident & CEOJan 20Option Exercise6.005,00030,000310,589Jan 22 04:35 PM
Blum Robert IPresident & CEOJan 20Sale20.415,000102,042305,589Jan 22 04:35 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 14Option Exercise9.4212,500117,750162,324Jan 15 04:35 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 14Sale19.2512,500240,619150,441Jan 15 04:35 PM
Blum Robert IPresident & CEOJan 04Option Exercise6.005,00030,000310,589Jan 04 05:18 PM
Blum Robert IPresident & CEOJan 04Sale20.235,000101,135305,589Jan 04 05:18 PM
HENDERSON JOHN TDirectorDec 31Option Exercise12.9685811,1201,757Dec 31 04:55 PM
HENDERSON JOHN TDirectorDec 31Sale20.3185817,426899Dec 31 04:55 PM
Blum Robert IPresident & CEODec 16Option Exercise6.005,00030,000310,589Dec 18 04:20 PM
Blum Robert IPresident & CEODec 16Sale20.515,000102,551305,589Dec 18 04:20 PM
Cragg DavidSVP Human ResourcesDec 15Option Exercise9.4216,666156,994152,137Dec 17 06:05 PM
GAGE L PATRICKDirectorDec 15Option Exercise12.967,71699,99928,520Dec 15 06:09 PM
GAGE L PATRICKDirectorDec 15Sale21.007,716162,03820,804Dec 15 06:09 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 10Sale20.131,05221,177150,441Dec 10 05:06 PM
BVF PARTNERS L P/ILSee Explanaton of ResponsesDec 09Sale18.00430,9547,757,172463,244Dec 11 06:48 PM
Blum Robert IPresident & CEODec 04Option Exercise6.005,00030,000310,589Dec 04 05:58 PM
Blum Robert IPresident & CEODec 04Sale17.365,00086,798305,589Dec 04 05:58 PM
Blum Robert IPresident & CEONov 23Option Exercise6.005,00030,000309,868Nov 25 04:20 PM
Blum Robert IPresident & CEONov 23Sale15.735,00078,644304,868Nov 25 04:20 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 12Sale17.151,23121,112150,951Nov 16 04:48 PM
Blum Robert IPresident & CEONov 10Option Exercise6.005,00030,000309,868Nov 12 04:59 PM
Blum Robert IPresident & CEONov 10Sale16.505,00082,488304,868Nov 12 04:59 PM
Blum Robert IPresident & CEOOct 29Option Exercise6.005,00030,000309,868Oct 30 04:50 PM
Blum Robert IPresident & CEOOct 29Sale15.155,00075,773304,868Oct 30 04:50 PM
Blum Robert IPresident & CEOOct 13Option Exercise6.005,00030,000309,868Oct 14 04:53 PM
Blum Robert IPresident & CEOOct 13Sale15.945,00079,686304,868Oct 14 04:53 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 08Sale17.451,25821,952152,182Oct 08 05:08 PM
COSTA SANTO JDirectorOct 05Option Exercise9.4515,000141,75015,000Oct 05 05:53 PM
Jaw ChingSVP Finance & CFOOct 05Option Exercise10.0327,500275,70088,300Oct 05 08:23 PM
HENDERSON JOHN TDirectorOct 05Option Exercise12.963,00038,8802,399Oct 05 09:03 PM
Kaye Edward M. MDDirectorOct 05Option Exercise7.6120,000152,20020,000Oct 05 08:38 PM
SMITH SANDFORD DDirectorOct 05Option Exercise7.375,93643,7485,936Oct 05 09:11 PM
PARSHALL B LYNNEDirectorOct 05Option Exercise7.2350,311363,89820,000Oct 06 04:58 PM
PARSHALL B LYNNEDirectorOct 05Sale30.0050,3111,509,3300Oct 06 04:58 PM
SMITH SANDFORD DDirectorOct 05Sale30.005,936178,0800Oct 05 09:11 PM